Clinical Trial Update: Study Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating a combination of lenalidomide, ixazomib, dexamethasone, and daratumumab in newly diagnosed standard-risk multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Daratumumab (daratumumab)
• Lenalidomide (lenalidomide)
• ixazomib (ixazomib)

Snippet

Sponsor: University Hospital, Toulouse | Conditions: Multiple Myeloma | Phase 2 | Status: UNKNOWN